副粘病毒Tianjin株HN和F基因真核表达质粒的构建及其对幼鼠免疫效果的评价
|
摘要
副流感病毒可引起一系列的呼吸道疾病,哮吼(Croup)是副流感病毒感染的典型症状,其中以副流感病毒1型(hPIV1)感染最为明显,如果感染hPIV1的婴幼儿不及时入院治疗,患儿将出现严重的呼吸道感染症状,甚至危及生命,同时,婴幼儿人群hPIV1患病率将明显升高。不仅如此，它又可以累及成人。仙台病毒(Sendai Virus, SeV),也称鼠源副流感病毒1型,是负单链RNA病毒,仙台病毒可以引起多种啮齿类动物呼吸道疾病,甚至爆发致死性肺炎。仙台病毒感染宿主细胞由2种包膜糖蛋白HN和F介导,两种糖蛋白是主要保护性抗原。一项研究发现仙台病毒(鼠源副流感病毒1型)减毒活疫苗能够保护非洲绿猴免受人源副流感病毒1型的攻击,为仙台病毒抗原成分保护婴幼儿免受副流感病毒1型感染提供了实验依据,但hPIV1或SeV的F蛋白以及仙台病毒两种包膜糖蛋白HN和F的联合免疫效果的研究,文献未见报道。8年前从爆发急性呼吸道疾病的普通棉耳狨猴群体中分离出一株高血凝效价的病毒株,初步确认为仙台病毒,并将其命名为仙台病毒tianjin株,后更名为副粘病毒Tianjin株,近期研究提示Tianjin株为仙台病毒新的基因型。因此,我们以此株病毒构建HN基因和F基因真核表达质粒,单独或联合免疫幼鼠,观察它们在幼鼠体内的免疫应答和免疫保护作用,评价构建的真核表达质粒及其免疫方法的效果。
使用RT-PCR扩增病毒HN基因的全部编码区,HindⅢ和XbaⅠ双酶切后,定向插入pcDNA3真核表达载体,构建副粘病毒Tianjin株HN真核表达质粒；以病毒cDNA为模板,PCR扩增副粘病毒Tianjin株F基因的全部编码区,F基因片段与T载体连接,构建过渡质粒,EcoRⅠ和NotⅠ双酶切过渡质粒后,酶切片段定向插入pcDNA3真核表达载体,构建副粘病毒Tianjin株F真核表达质粒。两种真核表达质粒经PCR、酶切和测序鉴定,证明构建质粒结构正确。构建成功的HN基因和F基因真核表达质粒为下一步的体外表达和动物免疫实验奠定了基础。
成功构建的HN基因和F基因真核表达质粒分别命名为pcDNA.HN和pcDNA.F,质粒经去内毒素处理后,借助阳离子脂质体转染COS7细胞,进行瞬时表达,应用RT-PCR、免疫荧光技术和ELISA方法检测重组子在COS7细胞的转录和翻译。RT-PCR结果提示pcDNA.HN和pcDNA.F可以在COS7细胞转录；间接免疫荧光结果显示转染细胞可见较弱的黄绿色荧光物质,而空质粒转染的COS7细胞未见有荧光物质出现；原位ELISA和使用细胞裂解物作为抗原的ELISA检测结果一致,并且均提示COS7细胞可以表达抗原蛋白。证明表达成功的HN基因和F基因真核表达质粒为动物免疫实验奠定了基础。
选取4-6周龄ICR幼鼠,肌内注射布比卡因预处理24h后,纯化的去内毒素的真核表达质粒pcDNA.HN和pcDNA.F单独或联合经肌内途径免疫幼鼠,动态观察幼鼠的免疫应答水平；4周后经鼻腔同株病毒攻击小鼠进行免疫保护实验,观察小鼠的存活情况、靶器官的变化和免疫应答水平。以灭活的副粘病毒Tianjin株加Al(OH)3佐剂作为阳性对照、空质粒pcDNA3和生理盐水作为阴性对照,通过小鼠存活率、脾脏和胸腺脏器比、肺组织病理变化、血凝抑制(HI)抗体、溶血抑制(HLI)抗体、B细胞和T细胞增殖反应、血清IgM和IgG抗体、细胞因子IFN-γ,IL-2和IL-4等指标评价副粘病毒Tianjin株HN基因和F基因真核表达质粒单独和联合使用的免疫效果。实验结果显示副粘病毒Tianjin株HN基因和F基因真核表达质粒可以很好地诱发幼鼠的体液免疫和细胞免疫应答,能够保护小鼠免受随后同株病毒的攻击；并且多项指标(B细胞刺激指数、T细胞刺激指数、血清IgM和IgG水平)显示副粘病毒Tianjin株HN基因真核表达质粒的免疫效果好于F基因真核表达质粒,同时小鼠存活率、肺脏病理学变化、HI抗体、HLI抗体、B细胞刺激指数、T细胞刺激指数,血清IgG水平、血清IFN-γ和IL-2水平等指标均显示联合免疫效果好于单独免疫效果。小鼠存活率、肺脏病理学变化、B细胞刺激指数、T细胞刺激指数、血清IgG抗体、血清IFN-γ和工L-2水平支持灭活病毒组幼鼠的免疫应答和免疫保护作用好于真核表达质粒单独使用的免疫效果,而灭活病毒组与联合质粒组的免疫效果之间的比较仍需进一步研究。
实验结果显示真核表达质粒pcDNA.HN和pcDNA.F联合免疫在预防幼鼠同株病毒呼吸道感染的效果明显,为副粘病毒Tianjin株包膜HN和F蛋白预防婴幼儿副流感病毒感染提供了实验动物依据。在现有的免疫方法不能有效预防婴幼儿副流感病毒感染的情况下,副粘病毒Tianjin株主要保护性抗原HN和F的DNA免疫不失为一种备选方案。
Parainfluenza virus has been known to be pathogen in a series of respiratory tract infections, among which croup is a typical sign of hPIV1 infection in children, if the infants and toddlers suffering from the hPIV1 infections can not be hospitalized and treated timely, not only will the infants have severe symptoms of respiratory tract infections, even endanger their lives, but the morbidity also appears to be significantly increased. In addition, hPIV1 infection also involved in adult patients. Sendai virus, also known as murine PIV1, a (-)ss RNA virus, gives rise to respiratory tract infections in many rodents, even results in fatal pneumonia among mice. The first step in the infection process is mediated by two kinds of envelope glycoproteins HN and F of the virion, which are main protective antigens as well. A study showed attenuated Sendai virus can protect Africa green monkey from challenge with hPIV1, it provides with experimental evidence that antigenic components of Sendai virus could protect infants human being from hPIV1 infections. However the research on immunization of F glycoprotein of hPIV1 or SeV and of combination of HN and F glycoproteins of Sendai virus was poorly understood, a strain of virus possessing high HA titer was isolated from common cotton-eared marmosets suffering from acute respiratory tract infection, it was verified primarily as a strain of Sendai virus so that Sendai virus, tianjin strain was then designated at the first place and Paramyxovirus, Tianjin strain was renamed later, current research shows the virus could be a new genotype of Sendai virus. therefore, eukaryotic expression vectors harbouring HN and F gene of the Sendai virus were constructed and given solely and jointly to infant mice, its immune response and immunological protection against subsequent infection were observed in order to evaluate these constructs and their administration approaches. HN coding region of the viral genome was amplified using RT-PCR, after the PCR product was digested by both HindⅢand Xba I, it was inserted unilaterally into downstream of Pcmv of pcDNA3 and eukaryotic expression vector harbouring HN gene of Paramyxovirus, Tianjin strain was then constructed. On the other hand, F coding region of the genome was amplified by PCR using its cDNA as template, and then F PCR products and T vector was ligated together to construct transitional plasmid which makes it easier for the plasmid to be digested by both EcoR I and Not I, the enzyme-digested fragment was later inserted to pcDNA3 as it did the case of HN. Both constructs were confirmed by such protocols as PCR, RE digestion and sequencing.
Successfully-constructed eukaryotic expression vectors were designated as pcDNA.HN and pcDNA.F respectively, both constructs transfected'COS7 cell for instant expression with the aid of cation liposome after being de-endotoxinated, their transcription and translation were then checked by protocols such as RT-PCR, IFA and ELISA. RT-PCR results showed both pcDNA.HN and pcDNA.F can transcript mRNA in COS7 cell. In addition, IFA showed that pale greenyellow fluorescence substance was seen in the construct-transfected cells whereas no fluorescence stain in the pcDNA3-transfected cells. Furthermore, both ELISA in situ and ELISA of cell lysate produced similar results that both construct can trigger translation in COS7 cell.
De-endotoxinated recombinant pcDNA.HN and pcDNA.F were administrated solely and jointly via intramuscular route in 4-6 week old infant ICR mice after pre-treated the mice with bupivacaine, their immunization was monitored on a regular weekly basis. The immunological protection test was carried out by challenging the mice population with the same strain of the virus after the mice had been inoculated three times for 4 weeks, and its protective outcomes were examined by variables such as survival rate, target organ responses and immune response, that is, variables such as survival rates, spleen index, thymus index, pathology of lung, sera HI titer, sera HLI titer, SI of lymphocyte B&T, sera IgM&IgG level, sera IFN-γ, IL-2 and IL-4 level were employed for immunological evaluation, compared to inactivated Paramyxovirus, Tianjin strain as positive control, and to both pcDNA3 and NS as negative control. the experiment results showed combination of pcDNA.HN and pcDNA.F can efficiently induce humoral immunity and cellular mediated immunity, so that these recombinants can protect the mice against subsequent challenge with the same strain of the virus. At the same time, many variables including SI of lymphocyte B&T, sera IgM&IgG level manifested the immune response induced by pcDNA.HN seemed to be better than that of pcDNA.F, most variables such as survival rates, pathology of lung, sera HI and HLI titer, SI of lymphocyte B&T, sera IgG level, sera IFN-y and IL-2 level indicated that combination approach seemed to be superior to that of sole one. Variables such as survival rate, pathology of lung, SI of lymphocyte B&T, sera IgG level, sera IFN-y and IL-2 level support an idea that immunization induced by the inactivated'virus appeared to be more effective than that of pcDNA.HN or pcDNA.F, nevertheless, the immunization compared between the construct combination and the inactivated virus needs to be further confirmed.
In summary, combination approach of pcDNA.HN and pcDNA.F had satisfactory performance on preventing infant mice from respiratory tract infections by Paramyxovirus, Tianjin strain, it laid experimental foundation upon which the viral envelope glycoproteins HN and F prevent infant from hPIV1-related infections. Under such circumstance that current approach has no effective preventive intervention against hPIV1 infections in infant, should the main protective antigens HN and F's DNA immunization be considered as a alternative to prevent hPIV1 infections.
使用RT-PCR扩增病毒HN基因的全部编码区,HindⅢ和XbaⅠ双酶切后,定向插入pcDNA3真核表达载体,构建副粘病毒Tianjin株HN真核表达质粒；以病毒cDNA为模板,PCR扩增副粘病毒Tianjin株F基因的全部编码区,F基因片段与T载体连接,构建过渡质粒,EcoRⅠ和NotⅠ双酶切过渡质粒后,酶切片段定向插入pcDNA3真核表达载体,构建副粘病毒Tianjin株F真核表达质粒。两种真核表达质粒经PCR、酶切和测序鉴定,证明构建质粒结构正确。构建成功的HN基因和F基因真核表达质粒为下一步的体外表达和动物免疫实验奠定了基础。
成功构建的HN基因和F基因真核表达质粒分别命名为pcDNA.HN和pcDNA.F,质粒经去内毒素处理后,借助阳离子脂质体转染COS7细胞,进行瞬时表达,应用RT-PCR、免疫荧光技术和ELISA方法检测重组子在COS7细胞的转录和翻译。RT-PCR结果提示pcDNA.HN和pcDNA.F可以在COS7细胞转录；间接免疫荧光结果显示转染细胞可见较弱的黄绿色荧光物质,而空质粒转染的COS7细胞未见有荧光物质出现；原位ELISA和使用细胞裂解物作为抗原的ELISA检测结果一致,并且均提示COS7细胞可以表达抗原蛋白。证明表达成功的HN基因和F基因真核表达质粒为动物免疫实验奠定了基础。
选取4-6周龄ICR幼鼠,肌内注射布比卡因预处理24h后,纯化的去内毒素的真核表达质粒pcDNA.HN和pcDNA.F单独或联合经肌内途径免疫幼鼠,动态观察幼鼠的免疫应答水平；4周后经鼻腔同株病毒攻击小鼠进行免疫保护实验,观察小鼠的存活情况、靶器官的变化和免疫应答水平。以灭活的副粘病毒Tianjin株加Al(OH)3佐剂作为阳性对照、空质粒pcDNA3和生理盐水作为阴性对照,通过小鼠存活率、脾脏和胸腺脏器比、肺组织病理变化、血凝抑制(HI)抗体、溶血抑制(HLI)抗体、B细胞和T细胞增殖反应、血清IgM和IgG抗体、细胞因子IFN-γ,IL-2和IL-4等指标评价副粘病毒Tianjin株HN基因和F基因真核表达质粒单独和联合使用的免疫效果。实验结果显示副粘病毒Tianjin株HN基因和F基因真核表达质粒可以很好地诱发幼鼠的体液免疫和细胞免疫应答,能够保护小鼠免受随后同株病毒的攻击；并且多项指标(B细胞刺激指数、T细胞刺激指数、血清IgM和IgG水平)显示副粘病毒Tianjin株HN基因真核表达质粒的免疫效果好于F基因真核表达质粒,同时小鼠存活率、肺脏病理学变化、HI抗体、HLI抗体、B细胞刺激指数、T细胞刺激指数,血清IgG水平、血清IFN-γ和IL-2水平等指标均显示联合免疫效果好于单独免疫效果。小鼠存活率、肺脏病理学变化、B细胞刺激指数、T细胞刺激指数、血清IgG抗体、血清IFN-γ和工L-2水平支持灭活病毒组幼鼠的免疫应答和免疫保护作用好于真核表达质粒单独使用的免疫效果,而灭活病毒组与联合质粒组的免疫效果之间的比较仍需进一步研究。
实验结果显示真核表达质粒pcDNA.HN和pcDNA.F联合免疫在预防幼鼠同株病毒呼吸道感染的效果明显,为副粘病毒Tianjin株包膜HN和F蛋白预防婴幼儿副流感病毒感染提供了实验动物依据。在现有的免疫方法不能有效预防婴幼儿副流感病毒感染的情况下,副粘病毒Tianjin株主要保护性抗原HN和F的DNA免疫不失为一种备选方案。
Parainfluenza virus has been known to be pathogen in a series of respiratory tract infections, among which croup is a typical sign of hPIV1 infection in children, if the infants and toddlers suffering from the hPIV1 infections can not be hospitalized and treated timely, not only will the infants have severe symptoms of respiratory tract infections, even endanger their lives, but the morbidity also appears to be significantly increased. In addition, hPIV1 infection also involved in adult patients. Sendai virus, also known as murine PIV1, a (-)ss RNA virus, gives rise to respiratory tract infections in many rodents, even results in fatal pneumonia among mice. The first step in the infection process is mediated by two kinds of envelope glycoproteins HN and F of the virion, which are main protective antigens as well. A study showed attenuated Sendai virus can protect Africa green monkey from challenge with hPIV1, it provides with experimental evidence that antigenic components of Sendai virus could protect infants human being from hPIV1 infections. However the research on immunization of F glycoprotein of hPIV1 or SeV and of combination of HN and F glycoproteins of Sendai virus was poorly understood, a strain of virus possessing high HA titer was isolated from common cotton-eared marmosets suffering from acute respiratory tract infection, it was verified primarily as a strain of Sendai virus so that Sendai virus, tianjin strain was then designated at the first place and Paramyxovirus, Tianjin strain was renamed later, current research shows the virus could be a new genotype of Sendai virus. therefore, eukaryotic expression vectors harbouring HN and F gene of the Sendai virus were constructed and given solely and jointly to infant mice, its immune response and immunological protection against subsequent infection were observed in order to evaluate these constructs and their administration approaches. HN coding region of the viral genome was amplified using RT-PCR, after the PCR product was digested by both HindⅢand Xba I, it was inserted unilaterally into downstream of Pcmv of pcDNA3 and eukaryotic expression vector harbouring HN gene of Paramyxovirus, Tianjin strain was then constructed. On the other hand, F coding region of the genome was amplified by PCR using its cDNA as template, and then F PCR products and T vector was ligated together to construct transitional plasmid which makes it easier for the plasmid to be digested by both EcoR I and Not I, the enzyme-digested fragment was later inserted to pcDNA3 as it did the case of HN. Both constructs were confirmed by such protocols as PCR, RE digestion and sequencing.
Successfully-constructed eukaryotic expression vectors were designated as pcDNA.HN and pcDNA.F respectively, both constructs transfected'COS7 cell for instant expression with the aid of cation liposome after being de-endotoxinated, their transcription and translation were then checked by protocols such as RT-PCR, IFA and ELISA. RT-PCR results showed both pcDNA.HN and pcDNA.F can transcript mRNA in COS7 cell. In addition, IFA showed that pale greenyellow fluorescence substance was seen in the construct-transfected cells whereas no fluorescence stain in the pcDNA3-transfected cells. Furthermore, both ELISA in situ and ELISA of cell lysate produced similar results that both construct can trigger translation in COS7 cell.
De-endotoxinated recombinant pcDNA.HN and pcDNA.F were administrated solely and jointly via intramuscular route in 4-6 week old infant ICR mice after pre-treated the mice with bupivacaine, their immunization was monitored on a regular weekly basis. The immunological protection test was carried out by challenging the mice population with the same strain of the virus after the mice had been inoculated three times for 4 weeks, and its protective outcomes were examined by variables such as survival rate, target organ responses and immune response, that is, variables such as survival rates, spleen index, thymus index, pathology of lung, sera HI titer, sera HLI titer, SI of lymphocyte B&T, sera IgM&IgG level, sera IFN-γ, IL-2 and IL-4 level were employed for immunological evaluation, compared to inactivated Paramyxovirus, Tianjin strain as positive control, and to both pcDNA3 and NS as negative control. the experiment results showed combination of pcDNA.HN and pcDNA.F can efficiently induce humoral immunity and cellular mediated immunity, so that these recombinants can protect the mice against subsequent challenge with the same strain of the virus. At the same time, many variables including SI of lymphocyte B&T, sera IgM&IgG level manifested the immune response induced by pcDNA.HN seemed to be better than that of pcDNA.F, most variables such as survival rates, pathology of lung, sera HI and HLI titer, SI of lymphocyte B&T, sera IgG level, sera IFN-y and IL-2 level indicated that combination approach seemed to be superior to that of sole one. Variables such as survival rate, pathology of lung, SI of lymphocyte B&T, sera IgG level, sera IFN-y and IL-2 level support an idea that immunization induced by the inactivated'virus appeared to be more effective than that of pcDNA.HN or pcDNA.F, nevertheless, the immunization compared between the construct combination and the inactivated virus needs to be further confirmed.
In summary, combination approach of pcDNA.HN and pcDNA.F had satisfactory performance on preventing infant mice from respiratory tract infections by Paramyxovirus, Tianjin strain, it laid experimental foundation upon which the viral envelope glycoproteins HN and F prevent infant from hPIV1-related infections. Under such circumstance that current approach has no effective preventive intervention against hPIV1 infections in infant, should the main protective antigens HN and F's DNA immunization be considered as a alternative to prevent hPIV1 infections.
引文
[1]Homa FL, Brideau RJ, Lehman DJ, Thomsen DR, Olmsted RA, Wathen MW. Development of a novel subunit vaccine that protects cotton rats against both human respiratory syncytial virus and human parainfluenza virus type 3 [J]. J Gen Virol.1993; 74 (Pt 9):1995-9
[2]Counihan ME, Sha DK, Holman RC, et al. Human parainfluenza virus-associated hospitalizations among children less than five years of age in the United States [J]. Pediatr Infect Dis J.2001; 20(7):646-653
[3]Echevarria JE, Erdman DD, Meissner HC, et al. Rapid molecular epidemiologic studies of human parainfluenza viruse based on direct sequencing of amplified DNA from a multiplex RT-PCR assay [J]. J Virol Methods.2000; 88(1):105-109
[4]Marx A,. Gary HE Jr, Marston BJ, et al. Parainfluenza virus infection among adults hospitalized for lower respiratory tract infection [J]. Clin Infect Dis.1999; 29(1):134-40
[5]农光民,谢湘芝等.小儿呼吸道感染病毒病原学研究[J].广西医科大学学报.1996；13(4)：30-32
[6]金玉,李宇宁,段红梅等.兰州地区急性呼吸道感染患儿病毒病原学研究[J].中国当代儿科杂志.2001；3(3)：315-316
[7]王同权,何亚香,季正华.快速检测小儿肺炎病毒体1615例报告[J].苏州医学院学报.1995；15(1)：153
[8]Sangster M, Smith FS, Coleclough C, Hurwitz JL. Human parainfluenza virus type 1 immunization of infant mice protects from subsequent Sendai virus infection [J]. Virology.1995; 212(1):13-9
[9]Hiroshi Komada, Shigeru Kusagawa, Claes Orvell, et al Antigenic diversity of human parainfluenza virus type 1 isolates and their immunological relationshiip with Sendai virus revealed by using monoclonal antibodies [J]. J General Virol.1992; 73:875-884.
[10]Blumberg BM, Giorgi C, Rose K, et al. Preparation and analysis of the nucleocapsid proteins of vesicular stomatitis virus and sendai virus, and analysis of the sendai virus leader-NP gene region [J]. J Gen Virol.1984; 65:769-779
[11]Van Wyke Coelingh KL, Winter CC, et al. Nucleotide and deduced amino acid sequence of hemagglutinin-neuraminidase genes of human type 3 parainfluenza viruses isolated from 1957 to 1983 [J]. Virology.1988; 162(1):137-143
[12]Sakai Y, Suzu S, Shioda T, et al. Nucleotide sequence of the bovine parainfluenza 3 virus genome:its 3'end and the genes of NP, P, C and M proteins [J]. Nucleic Acids Res.1987; 15(7): 2927-44
[13]Ohsawa K, Yamada A, Takeuchi K, et al. Genetic characterization of parainfluenza virus 3 derived from guinea pigs [J]. J:Vet. Med. Sci.1998; 60(8):919-922
[14]Bernard Nf, David MK, peter MH, et al. Fundamental Viology.3rd edition [M]. USA: Lippincott-Raven Publishers,1996
[15]Galinski MS, Mink MA, Pons MW. Molecular cloning and sequence analysis of the human parainfluenza 3 virus genes encoding the surface glycoproteins, F and HN. Virus Res [J].1987; 8(3):205-215
[16]Suzu S, Sakai Y, Shioda T, et al. Nucleotide sequence of the bovine parainfluenza 3 virus genome:the genes of the F and HN glycoproteins [J]. Nucleic Acids Res.1987; 15(7):2945-58
[17]Nishio M, Tsurudome M, Komada H, et al. Fusion properties of cells consitutively expressing human parainfluenza virus type 4A haemagglutinin-neuraminidase and fusion glycoproteins [J]. J Gen Virol.1994; 75:3517-23
[18]Yoshima H, Nakanishi M, Okada Y, et al. Carbohydrate structures of HVJ(Sendai virus) glycoproteins [J]. J Biol Chem.1981; 256(11):5355-5361
[19]胡建红,中西真人,齐义鹏.非编码序列对仙台病毒HN基因表达的调控作用[J].中国科学.1999；29(3)
[20]Hetherington SV, Watson AS, Scroggs RA, et al. Human parainfluenza virus type 1 evolution combines cocirculation of strains and development of geographically restricted lineages [J]. J Infect Dis.1994; 169(2):248-252
[21]Parrott RH, Kim HW, Brandt CD, Chanock RM. Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses [J]. Virus Res. 1988；11(1):1-15
[22]Hurwitz JL, Soike KF, Sangster MY, Portner A, Sealy RE, Dawson DH, Coleclough C. Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one [J]. Vaccine.1997; 15(5):533-40
[23]刘春燕,张媛媛,姚薇等.仙台病毒在儿童急性呼吸道感染中的血清学调查[J].天津医科大学学报.2004；10(3)：378-379
[24]李梅.单纯疱疹病毒Ⅰ、Ⅱ重组型共同抗原gD在大肠杆菌中的表达与临床诊断中的初步应用[D].天津：天津医科大学,2001：
[25]金冬雁,黎孟枫译.分子克隆实验指南第2版[M].北京：科学出版社,1996
[26]何健民,李晓眠,李梅,石立莹.仙台病毒引起婴幼儿呼吸道感染的血清学调查[J]. 中国儿童保健杂志2004；12(5)：439-440
[27]Takemasa Sakaguchi, Shin-ichi Takao, Katsuhiro Kiyotani, et al Expression of the HN, F, NP and M proteins of Sendai virus by recombinant vaccinia viruses and their contribution to protective immunity against Sendai virus infections in mice [J]. J General Virol.1993; 74:479-484.
[28]Piga N, Kessler N, Layani MP, Aymard M. Correlation between the reactivity patterns of monoclonal antibodies to distinct antigenic sites on HN glycoprotein and their protective abilities in Sendai (6/94) virus infection [J]. Arch Virol.1990; 110(3-4):179-93
[29]Skiadopoulos MH, Surman SR, Riggs JM, et al. Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeysand chimpanzees [J]. Virology.2002; 297(1):153-60
[30]Dave VP, Allan JE, Slobod KS, Smith FS, Ryan KW, Takimoto T, Power UF, Portner A, Hurwitz JL. Viral cross-reactivity and antigenic determinants recognized by human parainfluenza virus type 1-specific cytotoxic T-cells [J]. Virology.1994;199(2):376-83
[31]Lyn Deborah, Mazanec Mary, Nedrud John, et al Location of animo acid residues improtant for the structure and biological function of the haemagglutinin-neuraminidase glycoprotein of Sendai virus by analysis of escape mutants [J]. J General Virol.1991; 72:817-824.
[32]Portner A, Scroggs RA, Naeve CW. The fusion glycoprotein of Sendai virus:sequence analysis of an epitope involved in fusion and virus neutralization [J]. Virology. 1987;157(2):556-9.
[33]赵锴.病毒疫苗的研究现状与展望[J].第二军医大学学报2002；23(8)：813-815
[34]Cohen J. DNA points way to vaccines [news] [J]. Science.1993; 259(6):1691-1692
[35]Dudas RA, Karron RA. Respiratory syncytial virus vaccines [J]. Clin Microbiol Rev 1998; 11(3):430-9
[36]Kim JJ, Ayyavoo V, Bgarazzi ML, et al. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen [J]. J Immunol.1997; 158:816-826
[37]Xiang ZQ, and Erd HCJ. Manipulation of the immune response to a plasmid-encoded viral antigen by coinocultion with plasmids expressing cytokines [J]. Immunity.1995; 2:129-135
[38]Haanes EJ, Guimond P, Wardley R. The bovine parainfluenza virus type-3 (BPIV-3) hemagglutinin/neuraminidase glycoprotein expressed in baculovirus protects calves against experimental BPIV-3 challenge [J]. Vaccine.1997; 15(11):1288
[39]Haller AA, Miller T, Mitiku M, Coelingh K. Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector [J]. J Virol.2000; 74(24):11626-35
[40]Andersson C, Liljestrom P, Stahl S, Power UF. Protection against respiratory syncytial virus (RSV) elicited in mice by plasmid DNA immunisation encoding a secreted RSV G protein-derived antigen [J]. FEMS Immunol Med Microbiol.2000;29(4):247-53
[41]Schmidt AC, McAuliffe JM, Murphy BR, Collins PL. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3 [J]. J Virol.2001;75(10):4594-603
[42]Sakaguchi M, Nakamura H, Sonoda K, Hamada F, Hirai K. Protection of chickens from Newcastle disease by vaccination with a linear plasmid DNA expressing the F protein of Newcastle disease virus [J]. Vaccine.1996;14(8):747-52
[43]Tao T, Skiadopoulos MH, Davoodi F, Surman SR, Collins PL, Murphy BR. Construction of a live-attenuated bivalent vaccine virus against human parainfluenza virus (PIV) types 1 and 2 using a recombinant PIV3 backbone [J]. Vaccine.2001;19(27):3620-31
[44]Andersson C, Liljestrom P, Stahl S, Power UF Protection against respiratory syncytial virus (RSV) elicited in mice by plasmid DNA immunisation encoding a secreted RSV G protein-derived antigen [J]. FEMS Immunol Med Microbiol.2000;29(4):247-53
[45]Polack FP, Lee SH, Permar S, Manyara E, Nousari HG, Jeng Y, Mustafa F, Valsamakis A, Adams RJ, Robinson HL, Griffin DE. Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles [J]. Nat Med.2000; 6(7):744-5.
[46]Schlereth B, Germann PQ ter Meulen V, Niewiesk S. DNA vaccination with both the haemagglutinin and fusion proteins but not the nucleocapsid protein protects against experimental measles virus infection [J]. J Gen Virol.2000; 81 Pt 5:1321-5
[47]Li X, Sambhara S, Li CX, Ettorre L, Switzer I, Cates G, James O, Parrington M, Oomen R, Du RP, Klein M. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate [J]. Virology.2000; 269(1):54-65
[48]van Drunen Littel-van den Hurk S, Braun RP, Karvonen BC, King T, Yoo D, Babiuk LA. Immune responses and protection induced by DNA. vaccines encoding bovine parainfluenza virus type 3 glycoproteins [J]. Virology.1999; 260(1):35-46
[49]赵凯,邹仕平,张震宇,郑兆鑫,徐泉兴,尤永进,朱彩珠,冯霞.抗O型口蹄疫病毒 DNA疫苗的建立[J].中国免疫学杂志.2002；2：89
[50]伍欣星,盛德乔,王宇哲等.人乳头瘤病毒16型E7核酸疫苗的构建及鉴定[J].上海免疫学杂志.1999；19(6)：348-351
[51]徐建青,司静懿,刘世德等.DNA疫苗[J].国外医学·免疫学分册.1998；21(2)：82-86
[52]Murphy BR, Prince GA, Collins PL, Van Wyke Coelingh K, Olmsted RA, Spriggs MK, Chow YH, Huang WL, Cli WK, et al. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2 [J]. J Virol.1997; 71: 169-178.
[53]Honer AA, Van Uden JH, Zubeldia JM, et al. DNA-based immunotherapeutics for the treatment of allergic disease [J]. Immuological Reviews.2001; 179:102-18
[54]Osterhaus AD, de Vries P. Vaccination against acute respiratory virus infections and measles in man [J]. Immunobiology.1992; 184(2-3):180-92
[55]Crowe JE Jr. Respiratory syncytial virus vaccine development [J]. Vaccine.2001; 20 Suppl 1:S32-7
[56]Conry KM, Widera G, LoBuglio AF, et al. Selected strategies to augment polynucleotide immunization [J]. Gene Ther. 1996; 273(5):352-354
[57]张以芳,王生奎.影响核酸疫苗免疫效果的因素及提高核酸疫苗免疫效果的方法[J].黑龙江畜牧兽医.2000；3：24
[58]魏林,戴建新,孙树汉.新城疫病毒HN基因真核表达质粒的构建及其抗肿瘤作用的初步研究[J].第二军医大学学报.2000；21(6)：515-518
[59]严杰,罗海波,陆德源.现代微生物学实验技术及其应用[M].北京：人民卫生出版社,1997：194
[60]胡建红,齐兵,仙台病毒血凝素神经氨酸酶在哺乳动物细胞中的转录和翻译[J].生物化学与生物物理学报.2000；32(3)：229-234
[61]黄祯祥主编.医学病毒学基础及实验技术[M].北京：科学出版社,1990：142-148
[62]罗开健,辛朝安.禽流感油乳剂灭活疫苗的研制[J].中国兽医杂志.2001；37(4)：6-9
[63]裘法祖,沈关心等主编.现代免疫学实验技术[M].湖北：湖北科学技术出版社,2002.
[64]常见病毒病实验技术[M].北京：科学出版社,1976：47-48
[65]Nicole Kessler, Michele Aymard, Agnes Calvet. Study of a New Strain of Paramyxoviruses Isolated from Wild Ducks:Antigenic and Biological Properties [J]. J. Genl Virol. 1979;43:273-282
[66]曹洪欣,徐建勋.安替威胶囊对免疫抑制小鼠免疫功能的影响[J].中国医学理论与实 践.2004；(14)12.
[67]顾饶胜,何玲.纳络酮对铝中毒小鼠免疫功能的改善作用[J].第四军医大学吉林军医学院学报.2000；(22)1.
[68]李和军,郑祥雄.反义CD40 RNA对健康人B淋巴细胞功能的影响[J].中华新医学.2003；(4)11.
[69]于良,吴胜利.白藜芦醇及与环孢菌素A联用对人外周血T细胞免疫功能的影响[J].细胞与分子免疫学杂志.2003；19(6).
[70]Yasuko Maeda, Masato Hatta, Ayato Takada, et al. Live Bivalent Vaccine for Parainfluenza and Imfluenza Virus Infections [J]. J virol.2005;6:6674-6679
[71]Hsu SC, Obeid OE, Collins M, Iqbal M, Chargelegue D, Steward MW. Protective cytotoxic T lymphocyte responses against paramyxoviruses induced by epitope-based DNA vaccines: involvement of IFN-gamma [J]. Int Immunol.1998;10(10):1441-7
[72]Slobod kS，Shenep JL，Lujan Zilbermann J,et al滴鼻鼠1型副流感病毒(仙台病毒)对健康成人的安全性与免疫原性[J].Vaccine.2004；22：3182-3186
[73]Wollff JA, Malone, RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo [J]. Science.1990; 247:1465-8
[74]Klinman DM, SeECHLER JMG, Conover J, et al. Contribution of cells at the site of DNA vaccinaton to the generation of antigen-specific immunity and memory[J]. J Immunol. 1998,160:2388-2392
[75]许崇波核酸疫苗研究进展[J].畜牧与兽医.1998；4：179-180
[76]Butts C, Zubkoff I, Robbins DS, Cao S, Sarzotti M. DNA immunization of infants:potential and limitations [J]. Vaccine.1998; 16(14-15):1444-9
[77]赵平核酸疫苗作为治疗性疫苗的前景.免疫学杂志.2000；2：155-157
[78]Miyamae T. Selection of the most efficacious of twenty-two inactivated Sendai virus nasal vaccines by determination of the protection index in mice [J]. Lab Anim Sci.1999; 49(2):149-52
[79]Tsukui M, Ito H, Tada M, Nakata M, Miyajima H, Fujiwara K. Protective effect of inactivated virus vaccine on Sendai virus infection in rats [J]. Lab Anim Sci.1982; 32(2):143-6
[80]Miyamae T. Protective effects of nasal immunization in mice with various kinds of inactivated Sendai virus vaccines [J]. Microbiol Immunol.1986;30(6):following 597
[81]Takimoto K, Nakayama K, Yabe M, Ami Y, Yamada YK, Tamura S, Suzuki Y, Asano T, Saito M. Contamination of mouse-adapted influenza virus with Sendai virus [J]. Exp Anim.1998; 47(2):137-40
[82]Maru M, Haraguchi M, Sato K, Hotta H, Homma M. Evaluation of a protease activation mutant of Sendai virus as a potent live vaccine [J]. Vet Microbiol.1992;30(1):1-12
[83]申之义,李利萍,杜克勤,赵文双,李平安.兔病毒性出血症灭活疫苗的研究[J].中国动物检疫.2003；20(5)：24
[84]金博,程留芳,孙涛.剂量和佐剂对丙型肝炎病毒脱氧核糖核酸疫苗免疫效果的影响[J].海军总医院学报.2005；3：140-145
[85]Danko I. Wollf JA. Direct gene transfer into muscle[J]. Vaccine.1994; 12(16):1499-1502
[86]Lee SW, Sung YC, Immunostimulatory effects of bacterial derived plasmid depend on the mature of the antigen in intramuscular DNA inoculations [J]. Immunol.1998; 94:285-289
[87]Danko I, Fritz JD, Jiao S. et al. Pharmacological enhancement of in vivo foreign gene expression in muscle [J]. Gene Ther.1994; 1:114-121
[88]Nedrud JG, Liang XP, Hague N, Lamm ME. Combined oral/nasal immunization protects mice from Sendai virus infection [J]. J Immunol.1987; 139(10):3484-92
[89]Gurunathan S, Klinman DM, Seder RA. DNA vaccine:immunology, application and optimization [J]. Annu Rev Immunol.2000; 18:927-974
[90]Ertl H C, Xiang Z Q. Genetic Immunization [J]. Viral Immunology.1996; 9:1-9
[91]Ito H, Matumoto M. Protective efficacy of intranasal vaccination with subunit Sendai virus vaccine in mice [J]. Jpn J Exp Med.1986; 56(3):125-9
[92]Tashiro M, Homma M. Protection of mice from wild-type Sendai virus infection by a trypsin-resistant mutant, TR-2 [J]. J Virol.1985;53(1):228-34
[93]Fukumi H, Takeuchi Y. Vaccination against parainfluenza 1 virus (typus muris) infection in order to eradicate this virus in colonies of laboratory animals [J]. Dev Biol Stand.1975; 28:477-81
[94]Maru M, Haraguchi M, Sato K, Hotta H, Homma M. Evaluation of a protease activation mutant of Sendai virus as a potent live vaccine [J]. Vet Microbiol.1992; 30(1):1-12
[95]Tashiro M, Fujii Y, Nakamura K, Homma M. Cell-mediated immunity induced in mice after vaccination with a protease activation mutant, TR-2, of Sendai virus [J]. J Virol.1988; 62(7):2490-7
[96]Ito H, Matumoto M. Protective efficacy of intranasal vaccination with subunit Sendai virus vaccine in mice [J]. Jpn J Exp Med.1986; 56(3):125-9
[97]Kunisawa J, Nakagawa S, Mayumi T. Pharmacotherapy by intracellular delivery of drugs using fusogenic liposomes:application to vaccine development [J]. Adv Drug Deliv Rev.2001; 52(3):177-86
[98]Sato Y, Roman M, Tighe H, et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization [J]. Science.1996; 273(5):352-354
[99]Xiang ZQ, He Z, Wang Y, et al. The effect of interferon-gamma on genetic immunization [J]. Vaccine.1997; 15:896-902
[100]Iwasaki A, Stiemholm BJN, Chan AK, et al. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecule and cytokine [J]. J Immunol.1997; 158: 4591-4601
[101]An LL, Whitton JL. A multivalent minigene vaccine, containing B-cell, cytotoxic T-lymphocyte, and Th epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen [J]. J Virol.1997; 71(3):2292-302
[102]Kim JJ, Bagarazzi ML, Trivedi N, et al. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule gene [J]. Nat. Biotechnol.1997; 15: 641-645
[103]Tuting T, Wilson CC, Martin DM, et al. Autologous human monocyte derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic t-cell responses in vitro:enhancement by cotransfection of genes encoding the Th1-basing cytokines IL-12 and IFN-alpha [J]. J Immunol.1998; 1139-1147
[104]Eo SK, Sujin lee, Sangjun Chun, et al. Modulation of immunity against Herpes Simplex Virus infection via mucosal genetic transfer of plasmid DNA encoding chemokines [J]. J Virology. 2001; 569-578
[105]Eo SK, Lee S, Kumaraguru U, et al. Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands [J]. Vaccine.2001; 19(32):4685-4693
[106]Sin JI, Kim JJ, Pachuk C, et al. DNA Vaccines Encoding Interleukin-8 and RANTES enhance antigen-specific Thl-type CD4+T-cell-mediated Protective immunity against herpes simplex virus type 2 in vivo [J]. J Virol.2000; 74(23):1173-80
[107]Sin JI, Kim JJ, Zhang D, et al. Modulation of cellular responses by plasmid CD40L:CD40L plasmid vactor enhance antigen-specific helper T cell typel CD4+T cell-mediated protective immunity against herpes simplex virus type 2 in vivo [J]. Hum Gene Ther. 2001; 12(9):1091-102
[108]杜德伟,吴学勤,李谨革等.HBsAg DNA疫苗诱导小鼠特异性细胞和体液免疫[J].天 津医药.2001；29(4)：217-219
[109]Sixt N, Cardoso A, Vallier A, Fayolle J, Buckland R, Wild TF. Canine distemper virus DNA vaccination induces humoral and cellular immunity and protects against a lethal intracerebral challenge [J]. J Virol.1998; 72(11):8472-6
[110]Fujii Y, Sakaguchi T, Kiyotani K, Huang C, Fukuhara N, Egi Y, Yoshida T. Involvement of the leader sequence in Sendai virus pathogenesis revealed by recovery of a pathogenic field isolate from cDNA [J]. J Virol.2002;76(17):8540-7
[111]Hirata T, Iida A, Shiraki-Iida T, Kitazato K, Kato A, Nagai Y, Hasegawa M. An improved method for recovery of F-defective Sendai virus expressing foreign genes from cloned cDNA [J]. J Virol Methods.2002; 104(2):125-33
[112]Lagging LM, Meyer K, Hoft D, et al. Immune responses to plasmid DNA encoding the hepatitis C virus core protein [J]. J Virol.1995; 69:5859-5863
[113]Notkins A. L. Immune mechanisms by which the spread of viral infections is stopped [J]. Cell. Immunol.1974; 11:478-483
[114]Kano M, Matano T, Kato A, Shioda T, Nagai Y. Induction of HIV-1-specific neutralizing antibodies in mice vaccinated with a recombinant Sendai virus vector [J]. Jpn J Infect Dis.2002; 55(2):59-60
[115]Bocchia M, Bronte V, Colombo M, et al. Antitummor vaccination where we stand [J]. Haematologica.2000; 85:1172-206.
[116]Newman JT, Surman SR, Riggs JM, et al. Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse genetics [J]. Virus Genes.2002; 24(1):77-92
[117]Barouch DH, Santra S, Steenbake TD, et al. Augmentation and suppression of immune responses to an HIV-1DNA vaccine by plasmid cytokine/Ig administration [J]. J Immunol.1998; 161:1875-1882
[118]Lim YS, Kang BY, Kim EJ, et al. Potentition of antigen-specific, TH1 immune responses by multiple DNA vaccination with an ovalbumin/interferon-r hybridconstruct [J].Immunol.1998; 94:135-141
[119]Flo J, Tisminetzks, Baralle F, et al. Modulation of the immune response to DNA vaccine by co-deliveery of costimulatory molecules [J]. Immunology.2000; 100(2):259-67
[120]Yankanchas MA. Long-term anti-nucleoprotein cellular and containing NP gene [J]. Cell Biol.1993;4:151-59
[121]Griesenbach U, Inoue M, Hasegawa M, Alton EW. Sendai virus for gene therapy and vaccination [J]. Curr Opin Mol Ther.2005; 7(4):346-52.
[122]Maeda Y, Hatta M, Takada A, Watanabe T, Goto H, Neumann G, Kawaoka Y Live bivalent vaccine for parainfluenza and influenza virus infections [J]. J Virol,2005; 79(11):6674-9
[123]Kato M, Igarashi H, Takeda A, Sasaki Y, Nakamura H, Kano M, Sata T, Iida A, Hasegawa M, Horie S, Higashihara E, Nagai Y, Matano T. Induction of Gag-specific T-cell responses by therapeutic immunization with a Gag-expressing Sendai virus vector in macaques chronically infected with simian-human immunodeficiency virus [J]. Vaccine.2005; 23(24):3166-73.
[124]Takimoto T, Hurwitz JL, Zhan X, Krishnamurthy S, Prouser C, Brown B, Coleclough C, Boyd K, Scroggs RA, Portner A, Slobod KS. Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus [J]. Viral Immunol.2005; 18(2):255-66.
[125]Slobod KS, Shenep JL, Lujan-Zilbermann J, Allison K, Brown B, Scroggs RA, Portner A, Coleclough C, Hurwitz JL. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults [J]. Vaccine.2004; 22(23-24):3182-6.
[126]Takimoto T, Hurwitz JL, Coleclough C, Prouser C, Krishnamurthy S, Zhan X, Boyd K, Scroggs RA, Brown B, Nagai Y, Portner A, Slobod KS. Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV [J]. J Virol.2004; 78(11):6043-7.
[127]Nagase T, Matsumoto D, Nagase M, et al Neurospheres From Human Adipose Tissue Transplanted Into Cultured Mouse Embryos can Contribute to Craniofacial Morphogenesis:A Preliminary Report[J]. J Craniofac Surg.2007;18(1):49-53.
[128]Luque LE, Russell CJ.Spring-Loaded Heptad Repeat Residues Regulate the Expression and Activation of the Paramyxovirus Fusion (F) Protein[J]. J Virol.2007;24
[129]Marq JB, Brini A, Kolakofsky D, Garcin D. Targeting of the Sendai virus C protein to the plasma membrane via a peptide-only membrane anchor[J]. J Virol.2007; 17
[130]Kato A, Kiyotani K, Kubota T, et al. Importance of Anti-Interferon Capacity of the Sendai Virus C Protein for Pathogenicity in Mice[J]. J Virol.2007;10
[131]Kurooka M, Kaneda Y. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells[J]. Cancer Res.2007 Jan 1;67(1):227-36.
[132]Mottet-Osman G, Iseni F, Pelet T et al. Suppression of the Sendai virus M protein through a novel siRNA approach inhibits viral particle production but does not affect viral RNA synthesis[J]. J Virol.2006;27
[133]Pietila TE, Veckman V, Lehtonen A et al. Multiple NF-kappaB and IFN regulatory factor family transcription factors regulate CCL19 gene expression in human monocyte-derived dendritic cells[J]. J Immunol.2007;178(1):253-61.
[134]Park JH, Seok SH, Baek MW et al. Microbiological monitoring of Guinea pigs reared conventionally at two breeding facilities in Korea[J]. Exp Anim.2006;55(5):427-32
[135]Kiyotani K, Sakaguchi T, Kato A et al. Paramyxovirus Sendai virus V protein counteracts innate virus clearance through IRF-3 activation, but not via interferon, in mice[J]. Virology. 2006;5
[136]Kuo E, Bharat A, Shih J et al. Role of airway epithelial injury in murine orthotopic tracheal allograft rejection[J]. Ann Thorac Surg.2006;82(4):1226-33
[137]Yount JS, Kraus TA, Horvath CM et al. A novel role for viral-defective interfering particles in enhancing dendritic cell maturation[J]. J Immunol.2006;177(7):4503-13
[138]Quang Lea T, Kawachia M, Yamada H, et al. Identification of trypsin I as a candidate for influenza A virus and Sendai virus envelope glycoprotein processing protease in rat brain[J]. Biol Chem.2006;387(9):1305
[139]Shibata S, Okano S, Yonemitsu Y, et al. Induction of efficient antitumor immunity using dendritic cells activated by recombinant Sendai virus and its modulation by exogenous IFN-beta gene[J]. J Immunol.2006;177(6):3564-76
[140]Bousse T, Takimoto T. Mutation at residue 523 creates a second receptor binding site on human parainfluenza virus type 1 hemagglutinin-neuraminidase protein[J]. J Virol. 2006;80(18):9009-16
[141]Yoshizaki M, Hironaka T, Iwasaki H, et al. Naked Sendai virus vector lacking all of the envelope-related genes:reduced cytopathogenicity and immunogenicity[J]. J Gene Med. 2006;8(9):1151-9
[142]Yamada H, Le QT, Kousaka A, et al. Sendai virus infection up-regulates trypsin I and matrix metalloproteinase-9 Triggering viral multiplication and matrix degradation in rat lungs and lung L2 cells[J]. Arch Virol.2006; 151 (12):2529-37
[143]Bousse T, Chambers RL, Scroggs RA,et al. Human parainfluenza virus type 1 but not Sendai virus replicates in human respiratory cells despite IFN treatment[J]. Virus Res. 2006;121(1):23-32
[144]Hirayama E, Hattori M, Kim J. Specific binding of heat shock protein 70 with HN-protein inhibits the HN-protein assembly in Sendai virus-infected Vero cells[J]. Virus Res.2006 Sep;120(1-2):199-207
[145]Nishio M, Nagata A, Yamamoto A, et al. The properties of recombinant Sendai virus having the P gene of Sendai virus pi strain derived from BHK cells persistently infected with Sendai virus[J]. Med Microbiol Immunol.2006; 195(3):151-8
[146]石建党.普通棉耳狨猴死亡病毒病因及与人群关系的研究[D].天津：天津医科大学,2002：
[147]石立莹.副粘病毒Tianjin株全基因组克隆、测序及生物信息学分析[D].天津：天津医科大学,2007：
[148]张国际,李晓眠,佟惠春.仙台病毒HN基因核酸疫苗的构建及初步鉴定[J].天津医药2005；(33)1：17-19
[1]Homa FL, Brideau RJ, Lehman DJ, Thomsen DR, Olmsted RA, Wathen MW, Development of a novel subunit vaccine that protects cotton rats against both human respiratory syncytial virus and human parainfluenza virus type 3 [J]. J Gen Virol.1993; 74 (Pt 9):1995-9
[2]Counihan ME, Sha DK, Holman RC, et al. Human parainfluenza virus-associated hospitalizations among children less than five years of age in the United States [J]. Pediatr Infect Dis J.2001; 20(7):646-653
[3]Echevarria JE, Erdman DD, Meissner HC, et al. Rapid molecular epidemiologic studies of human parainfluenza viruse based on direct sequencing of amplified DNA from a multiplex RT-PCR assay [J]. J Virol Methods.2000; 88(1):105-109
[4]农光民,谢湘芝等.小儿呼吸道感染病毒病原学研究[J].广西医科大学学报.1996；13(4)：30-32
[5]金玉,李宇宁,段红梅等.兰州地区急性呼吸道感染患儿病毒病原学研究[J].中国当代儿科杂志.2001；3(3)：315-316
[6]王同权,何亚香,季正华.快速检测小儿肺炎病毒体1615例报告[J].苏州医学院学报.1995；15(1)：153
[7]陈文彬.副流感病毒疫苗研制近展[J].国外医学预防诊断治疗用生物制品分册.2004(27)2：57
[8]赵锴.病毒疫苗的研究现状与展望[J].第二军医大学学报2002；23(8)：813-815
[9]徐建青,司静懿,刘世德等.DNA疫苗[J].国外医学·免疫学分册.1998；21(2)：82-86
[10]张以芳,王生奎.影响核酸疫苗免疫效果的因素及提高核酸疫苗免疫效果的方法[J].黑龙江畜牧兽医.2000；3：24
[11]许崇波核酸疫苗研究进展[J].畜牧与兽医.1998；4：179-180
[12]赵平核酸疫苗作为治疗性疫苗的前景.免疫学杂志.2000；2：155-157
[13]薛强,仇华吉,童光志.RNA病毒的反向遗传学[J].生物技术通报2001；4：1
[14]Andrew Pekosz, Biao He, Robert A Lamb. Reverse genetics of negative-strand RNA viruses: Closing the circle [J]. Proc Natl Acad Sci USA,1999,96(16):8804-8806.
[15]Kawashita Y, Fujioka H, Ohtsuru A, Kaneda Y, Kamohara Y, Kawazoe Y, Yamashita S, Kanematsu T.The efficacy and safety of gene transfer into the porcine liver in vivo by HVJ (Sendai virus) liposome [J]. Transplantation.2005,15;80(11):1623-9.
[16]Nishiyama K, Takaji K, Kataoka K, Kurihara Y, Yoshimura M, Kato A, Ogawa H, Kurihara H. Idl gene transfer confers angiogenic property on fully differentiated endothelial cells and contributes to therapeutic angiogenesis [J]. Circulation.2005,112(18):2840-50.
[17]Itani T, Kobayashi Y, Kuroda M, Ma N, Mifuji R, Urawa N, Tanaka Y, Kaito M, Adachi Y. Transfecting the multidrug resistance protein 2 gene improves transcellular organic anion transport [J]. Int J Mol Med.2005,16(5):821-5.
[18]Griesenbach U, Inoue M, Hasegawa M, Alton EW. Sendai virus for gene therapy and vaccination [J]. Curr Opin Mol Ther.2005,7(4):346-52.
[19]Verma SK, Mani P, Sharma NR, Krishnan A, Kumar VV, Reddy BS, Chaudhuri A, Roy RP, Sarkar DP. Histidylated lipid-modified Sendai viral envelopes mediate enhanced membrane fusion and potentiate targeted gene delivery [J]. J Biol Chem.2005,280(42):35399-409.
[20]Zimmer G, Bossow S, Kolesnikova L, Hinz M, Neubert WJ, Herrler G.A chimeric respiratory syncytial virus fusion protein functionally replaces the F and HN glycoproteins in recombinant Sendai virus [J]. J Virol.2005,79(16):10467-77.
[21]Takimoto T, Hurwitz JL, Zhan X, Krishnamurthy S, Prouser C, Brown B, Coleclough C, Boyd K, Scroggs RA, Portner A, Slobod KS. Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus [J]. Viral Immunol.2005;18(2):255-66.
[22]Maeda Y, Hatta M, Takada A, Watanabe T, Goto H, Neumann G, Kawaoka Y Live bivalent vaccine for parainfluenza and influenza virus infections [J]. J Virol.2005,79(11):6674-9.
[23]Kato N, Nemoto K, Nakanishi K, Morishita R, Kaneda Y, Uenoyama M, Ikeda T, Fujikawa K. Nonviral HVJ (hemagglutinating virus of Japan) liposome-mediated retrograde gene transfer of human hepatocyte growth factor into rat nervous system promotes functional and histological recovery of the crushed nerve [J]. Neurosci Res.2005,52(4):299-310.
[24]Hou X, Suquilanda E, Zeledon A, Kacsinta A, Moore A, Seto J, McQueen N. Mutations in Sendai virus variant F1-R that correlate with plaque formation in the absence of trypsin [J]. Med Microbiol Immunol (Berl).2005,194(3):129-36.
[25]Shigemura N, Sawa Y, Mizuno S, Ono M, Ohta M, Nakamura T, Kaneda Y, Matsuda H. Amelioration of pulmonary emphysema by in vivo gene transfection with hepatocyte growth factor in rats [J]. Circulation.2005,22;111(11):1407-14.
[26]Li K, Chen Z, Kato N, Gale M Jr, Lemon SM. Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes [J]. J Biol Chem.2005, 29;280(17):16739-47.
[27]Ning S, Huye LE, Pagano JS. Regulation of the transcriptional activity of the IRF7 promoter by a pathway independent of interferon signaling [J]. J Biol Chem.2005,280(13):12262-70.
[28]Takimoto T, Hurwitz JL, Coleclough C, Prouser C, Krishnamurthy S, Zhan X, Boyd K, Scroggs RA, Brown B, Nagai Y, Portner A, Slobod KS. Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV [J]. J Virol.2004,78(11):6043-7.
[29]Wu MH, Yokozeki H, Takagawa S, Yamamoto T, Satoh T, Kaneda Y, Katayama I, Nishioka K. Hepatocyte growth factor both prevents and ameliorates the symptoms of dermal sclerosis in a mouse model of scleroderma [J]. Gene Ther.2004,11(2):170-80.
[30]NamikiM, Kawashima S, Yamashita T, Ozaki M, Sakoda T, Inoue N, Hirata K, Morishita R, Kaneda Y, Yokoyama M. Intramuscular gene transfer of interleukin-10 cDNA reduces atherosclerosis in apolipoprotein E-knockout mice [J]. Atherosclerosis.2004,172(1):21-9.
[31]Cai X, Castleman WL. Early high expression of IP-10 in F344 rats resistant to Sendai virus-induced airway injury [J]. Am J Physiol Lung Cell Mol Physiol.2003,285(6):L1263-9.
[32]Haller AA, Miller T, Mitiku M, Coelingh K. Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector [J]. J Virol.2000; 74(24):11626-35
[33]Tao T, Skiadopoulos MH, Davoodi F, Surman SR, Collins PL, Murphy BR. Construction of a live-attenuated bivalent vaccine virus against human parainfluenza virus (PIV) types 1 and 2 using a recombinant PIV3 backbone [J]. Vaccine.2001; 19(27):3620-31
[2]Counihan ME, Sha DK, Holman RC, et al. Human parainfluenza virus-associated hospitalizations among children less than five years of age in the United States [J]. Pediatr Infect Dis J.2001; 20(7):646-653
[3]Echevarria JE, Erdman DD, Meissner HC, et al. Rapid molecular epidemiologic studies of human parainfluenza viruse based on direct sequencing of amplified DNA from a multiplex RT-PCR assay [J]. J Virol Methods.2000; 88(1):105-109
[4]Marx A,. Gary HE Jr, Marston BJ, et al. Parainfluenza virus infection among adults hospitalized for lower respiratory tract infection [J]. Clin Infect Dis.1999; 29(1):134-40
[5]农光民,谢湘芝等.小儿呼吸道感染病毒病原学研究[J].广西医科大学学报.1996；13(4)：30-32
[6]金玉,李宇宁,段红梅等.兰州地区急性呼吸道感染患儿病毒病原学研究[J].中国当代儿科杂志.2001；3(3)：315-316
[7]王同权,何亚香,季正华.快速检测小儿肺炎病毒体1615例报告[J].苏州医学院学报.1995；15(1)：153
[8]Sangster M, Smith FS, Coleclough C, Hurwitz JL. Human parainfluenza virus type 1 immunization of infant mice protects from subsequent Sendai virus infection [J]. Virology.1995; 212(1):13-9
[9]Hiroshi Komada, Shigeru Kusagawa, Claes Orvell, et al Antigenic diversity of human parainfluenza virus type 1 isolates and their immunological relationshiip with Sendai virus revealed by using monoclonal antibodies [J]. J General Virol.1992; 73:875-884.
[10]Blumberg BM, Giorgi C, Rose K, et al. Preparation and analysis of the nucleocapsid proteins of vesicular stomatitis virus and sendai virus, and analysis of the sendai virus leader-NP gene region [J]. J Gen Virol.1984; 65:769-779
[11]Van Wyke Coelingh KL, Winter CC, et al. Nucleotide and deduced amino acid sequence of hemagglutinin-neuraminidase genes of human type 3 parainfluenza viruses isolated from 1957 to 1983 [J]. Virology.1988; 162(1):137-143
[12]Sakai Y, Suzu S, Shioda T, et al. Nucleotide sequence of the bovine parainfluenza 3 virus genome:its 3'end and the genes of NP, P, C and M proteins [J]. Nucleic Acids Res.1987; 15(7): 2927-44
[13]Ohsawa K, Yamada A, Takeuchi K, et al. Genetic characterization of parainfluenza virus 3 derived from guinea pigs [J]. J:Vet. Med. Sci.1998; 60(8):919-922
[14]Bernard Nf, David MK, peter MH, et al. Fundamental Viology.3rd edition [M]. USA: Lippincott-Raven Publishers,1996
[15]Galinski MS, Mink MA, Pons MW. Molecular cloning and sequence analysis of the human parainfluenza 3 virus genes encoding the surface glycoproteins, F and HN. Virus Res [J].1987; 8(3):205-215
[16]Suzu S, Sakai Y, Shioda T, et al. Nucleotide sequence of the bovine parainfluenza 3 virus genome:the genes of the F and HN glycoproteins [J]. Nucleic Acids Res.1987; 15(7):2945-58
[17]Nishio M, Tsurudome M, Komada H, et al. Fusion properties of cells consitutively expressing human parainfluenza virus type 4A haemagglutinin-neuraminidase and fusion glycoproteins [J]. J Gen Virol.1994; 75:3517-23
[18]Yoshima H, Nakanishi M, Okada Y, et al. Carbohydrate structures of HVJ(Sendai virus) glycoproteins [J]. J Biol Chem.1981; 256(11):5355-5361
[19]胡建红,中西真人,齐义鹏.非编码序列对仙台病毒HN基因表达的调控作用[J].中国科学.1999；29(3)
[20]Hetherington SV, Watson AS, Scroggs RA, et al. Human parainfluenza virus type 1 evolution combines cocirculation of strains and development of geographically restricted lineages [J]. J Infect Dis.1994; 169(2):248-252
[21]Parrott RH, Kim HW, Brandt CD, Chanock RM. Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses [J]. Virus Res. 1988；11(1):1-15
[22]Hurwitz JL, Soike KF, Sangster MY, Portner A, Sealy RE, Dawson DH, Coleclough C. Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one [J]. Vaccine.1997; 15(5):533-40
[23]刘春燕,张媛媛,姚薇等.仙台病毒在儿童急性呼吸道感染中的血清学调查[J].天津医科大学学报.2004；10(3)：378-379
[24]李梅.单纯疱疹病毒Ⅰ、Ⅱ重组型共同抗原gD在大肠杆菌中的表达与临床诊断中的初步应用[D].天津：天津医科大学,2001：
[25]金冬雁,黎孟枫译.分子克隆实验指南第2版[M].北京：科学出版社,1996
[26]何健民,李晓眠,李梅,石立莹.仙台病毒引起婴幼儿呼吸道感染的血清学调查[J]. 中国儿童保健杂志2004；12(5)：439-440
[27]Takemasa Sakaguchi, Shin-ichi Takao, Katsuhiro Kiyotani, et al Expression of the HN, F, NP and M proteins of Sendai virus by recombinant vaccinia viruses and their contribution to protective immunity against Sendai virus infections in mice [J]. J General Virol.1993; 74:479-484.
[28]Piga N, Kessler N, Layani MP, Aymard M. Correlation between the reactivity patterns of monoclonal antibodies to distinct antigenic sites on HN glycoprotein and their protective abilities in Sendai (6/94) virus infection [J]. Arch Virol.1990; 110(3-4):179-93
[29]Skiadopoulos MH, Surman SR, Riggs JM, et al. Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeysand chimpanzees [J]. Virology.2002; 297(1):153-60
[30]Dave VP, Allan JE, Slobod KS, Smith FS, Ryan KW, Takimoto T, Power UF, Portner A, Hurwitz JL. Viral cross-reactivity and antigenic determinants recognized by human parainfluenza virus type 1-specific cytotoxic T-cells [J]. Virology.1994;199(2):376-83
[31]Lyn Deborah, Mazanec Mary, Nedrud John, et al Location of animo acid residues improtant for the structure and biological function of the haemagglutinin-neuraminidase glycoprotein of Sendai virus by analysis of escape mutants [J]. J General Virol.1991; 72:817-824.
[32]Portner A, Scroggs RA, Naeve CW. The fusion glycoprotein of Sendai virus:sequence analysis of an epitope involved in fusion and virus neutralization [J]. Virology. 1987;157(2):556-9.
[33]赵锴.病毒疫苗的研究现状与展望[J].第二军医大学学报2002；23(8)：813-815
[34]Cohen J. DNA points way to vaccines [news] [J]. Science.1993; 259(6):1691-1692
[35]Dudas RA, Karron RA. Respiratory syncytial virus vaccines [J]. Clin Microbiol Rev 1998; 11(3):430-9
[36]Kim JJ, Ayyavoo V, Bgarazzi ML, et al. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen [J]. J Immunol.1997; 158:816-826
[37]Xiang ZQ, and Erd HCJ. Manipulation of the immune response to a plasmid-encoded viral antigen by coinocultion with plasmids expressing cytokines [J]. Immunity.1995; 2:129-135
[38]Haanes EJ, Guimond P, Wardley R. The bovine parainfluenza virus type-3 (BPIV-3) hemagglutinin/neuraminidase glycoprotein expressed in baculovirus protects calves against experimental BPIV-3 challenge [J]. Vaccine.1997; 15(11):1288
[39]Haller AA, Miller T, Mitiku M, Coelingh K. Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector [J]. J Virol.2000; 74(24):11626-35
[40]Andersson C, Liljestrom P, Stahl S, Power UF. Protection against respiratory syncytial virus (RSV) elicited in mice by plasmid DNA immunisation encoding a secreted RSV G protein-derived antigen [J]. FEMS Immunol Med Microbiol.2000;29(4):247-53
[41]Schmidt AC, McAuliffe JM, Murphy BR, Collins PL. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3 [J]. J Virol.2001;75(10):4594-603
[42]Sakaguchi M, Nakamura H, Sonoda K, Hamada F, Hirai K. Protection of chickens from Newcastle disease by vaccination with a linear plasmid DNA expressing the F protein of Newcastle disease virus [J]. Vaccine.1996;14(8):747-52
[43]Tao T, Skiadopoulos MH, Davoodi F, Surman SR, Collins PL, Murphy BR. Construction of a live-attenuated bivalent vaccine virus against human parainfluenza virus (PIV) types 1 and 2 using a recombinant PIV3 backbone [J]. Vaccine.2001;19(27):3620-31
[44]Andersson C, Liljestrom P, Stahl S, Power UF Protection against respiratory syncytial virus (RSV) elicited in mice by plasmid DNA immunisation encoding a secreted RSV G protein-derived antigen [J]. FEMS Immunol Med Microbiol.2000;29(4):247-53
[45]Polack FP, Lee SH, Permar S, Manyara E, Nousari HG, Jeng Y, Mustafa F, Valsamakis A, Adams RJ, Robinson HL, Griffin DE. Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles [J]. Nat Med.2000; 6(7):744-5.
[46]Schlereth B, Germann PQ ter Meulen V, Niewiesk S. DNA vaccination with both the haemagglutinin and fusion proteins but not the nucleocapsid protein protects against experimental measles virus infection [J]. J Gen Virol.2000; 81 Pt 5:1321-5
[47]Li X, Sambhara S, Li CX, Ettorre L, Switzer I, Cates G, James O, Parrington M, Oomen R, Du RP, Klein M. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate [J]. Virology.2000; 269(1):54-65
[48]van Drunen Littel-van den Hurk S, Braun RP, Karvonen BC, King T, Yoo D, Babiuk LA. Immune responses and protection induced by DNA. vaccines encoding bovine parainfluenza virus type 3 glycoproteins [J]. Virology.1999; 260(1):35-46
[49]赵凯,邹仕平,张震宇,郑兆鑫,徐泉兴,尤永进,朱彩珠,冯霞.抗O型口蹄疫病毒 DNA疫苗的建立[J].中国免疫学杂志.2002；2：89
[50]伍欣星,盛德乔,王宇哲等.人乳头瘤病毒16型E7核酸疫苗的构建及鉴定[J].上海免疫学杂志.1999；19(6)：348-351
[51]徐建青,司静懿,刘世德等.DNA疫苗[J].国外医学·免疫学分册.1998；21(2)：82-86
[52]Murphy BR, Prince GA, Collins PL, Van Wyke Coelingh K, Olmsted RA, Spriggs MK, Chow YH, Huang WL, Cli WK, et al. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2 [J]. J Virol.1997; 71: 169-178.
[53]Honer AA, Van Uden JH, Zubeldia JM, et al. DNA-based immunotherapeutics for the treatment of allergic disease [J]. Immuological Reviews.2001; 179:102-18
[54]Osterhaus AD, de Vries P. Vaccination against acute respiratory virus infections and measles in man [J]. Immunobiology.1992; 184(2-3):180-92
[55]Crowe JE Jr. Respiratory syncytial virus vaccine development [J]. Vaccine.2001; 20 Suppl 1:S32-7
[56]Conry KM, Widera G, LoBuglio AF, et al. Selected strategies to augment polynucleotide immunization [J]. Gene Ther. 1996; 273(5):352-354
[57]张以芳,王生奎.影响核酸疫苗免疫效果的因素及提高核酸疫苗免疫效果的方法[J].黑龙江畜牧兽医.2000；3：24
[58]魏林,戴建新,孙树汉.新城疫病毒HN基因真核表达质粒的构建及其抗肿瘤作用的初步研究[J].第二军医大学学报.2000；21(6)：515-518
[59]严杰,罗海波,陆德源.现代微生物学实验技术及其应用[M].北京：人民卫生出版社,1997：194
[60]胡建红,齐兵,仙台病毒血凝素神经氨酸酶在哺乳动物细胞中的转录和翻译[J].生物化学与生物物理学报.2000；32(3)：229-234
[61]黄祯祥主编.医学病毒学基础及实验技术[M].北京：科学出版社,1990：142-148
[62]罗开健,辛朝安.禽流感油乳剂灭活疫苗的研制[J].中国兽医杂志.2001；37(4)：6-9
[63]裘法祖,沈关心等主编.现代免疫学实验技术[M].湖北：湖北科学技术出版社,2002.
[64]常见病毒病实验技术[M].北京：科学出版社,1976：47-48
[65]Nicole Kessler, Michele Aymard, Agnes Calvet. Study of a New Strain of Paramyxoviruses Isolated from Wild Ducks:Antigenic and Biological Properties [J]. J. Genl Virol. 1979;43:273-282
[66]曹洪欣,徐建勋.安替威胶囊对免疫抑制小鼠免疫功能的影响[J].中国医学理论与实 践.2004；(14)12.
[67]顾饶胜,何玲.纳络酮对铝中毒小鼠免疫功能的改善作用[J].第四军医大学吉林军医学院学报.2000；(22)1.
[68]李和军,郑祥雄.反义CD40 RNA对健康人B淋巴细胞功能的影响[J].中华新医学.2003；(4)11.
[69]于良,吴胜利.白藜芦醇及与环孢菌素A联用对人外周血T细胞免疫功能的影响[J].细胞与分子免疫学杂志.2003；19(6).
[70]Yasuko Maeda, Masato Hatta, Ayato Takada, et al. Live Bivalent Vaccine for Parainfluenza and Imfluenza Virus Infections [J]. J virol.2005;6:6674-6679
[71]Hsu SC, Obeid OE, Collins M, Iqbal M, Chargelegue D, Steward MW. Protective cytotoxic T lymphocyte responses against paramyxoviruses induced by epitope-based DNA vaccines: involvement of IFN-gamma [J]. Int Immunol.1998;10(10):1441-7
[72]Slobod kS，Shenep JL，Lujan Zilbermann J,et al滴鼻鼠1型副流感病毒(仙台病毒)对健康成人的安全性与免疫原性[J].Vaccine.2004；22：3182-3186
[73]Wollff JA, Malone, RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo [J]. Science.1990; 247:1465-8
[74]Klinman DM, SeECHLER JMG, Conover J, et al. Contribution of cells at the site of DNA vaccinaton to the generation of antigen-specific immunity and memory[J]. J Immunol. 1998,160:2388-2392
[75]许崇波核酸疫苗研究进展[J].畜牧与兽医.1998；4：179-180
[76]Butts C, Zubkoff I, Robbins DS, Cao S, Sarzotti M. DNA immunization of infants:potential and limitations [J]. Vaccine.1998; 16(14-15):1444-9
[77]赵平核酸疫苗作为治疗性疫苗的前景.免疫学杂志.2000；2：155-157
[78]Miyamae T. Selection of the most efficacious of twenty-two inactivated Sendai virus nasal vaccines by determination of the protection index in mice [J]. Lab Anim Sci.1999; 49(2):149-52
[79]Tsukui M, Ito H, Tada M, Nakata M, Miyajima H, Fujiwara K. Protective effect of inactivated virus vaccine on Sendai virus infection in rats [J]. Lab Anim Sci.1982; 32(2):143-6
[80]Miyamae T. Protective effects of nasal immunization in mice with various kinds of inactivated Sendai virus vaccines [J]. Microbiol Immunol.1986;30(6):following 597
[81]Takimoto K, Nakayama K, Yabe M, Ami Y, Yamada YK, Tamura S, Suzuki Y, Asano T, Saito M. Contamination of mouse-adapted influenza virus with Sendai virus [J]. Exp Anim.1998; 47(2):137-40
[82]Maru M, Haraguchi M, Sato K, Hotta H, Homma M. Evaluation of a protease activation mutant of Sendai virus as a potent live vaccine [J]. Vet Microbiol.1992;30(1):1-12
[83]申之义,李利萍,杜克勤,赵文双,李平安.兔病毒性出血症灭活疫苗的研究[J].中国动物检疫.2003；20(5)：24
[84]金博,程留芳,孙涛.剂量和佐剂对丙型肝炎病毒脱氧核糖核酸疫苗免疫效果的影响[J].海军总医院学报.2005；3：140-145
[85]Danko I. Wollf JA. Direct gene transfer into muscle[J]. Vaccine.1994; 12(16):1499-1502
[86]Lee SW, Sung YC, Immunostimulatory effects of bacterial derived plasmid depend on the mature of the antigen in intramuscular DNA inoculations [J]. Immunol.1998; 94:285-289
[87]Danko I, Fritz JD, Jiao S. et al. Pharmacological enhancement of in vivo foreign gene expression in muscle [J]. Gene Ther.1994; 1:114-121
[88]Nedrud JG, Liang XP, Hague N, Lamm ME. Combined oral/nasal immunization protects mice from Sendai virus infection [J]. J Immunol.1987; 139(10):3484-92
[89]Gurunathan S, Klinman DM, Seder RA. DNA vaccine:immunology, application and optimization [J]. Annu Rev Immunol.2000; 18:927-974
[90]Ertl H C, Xiang Z Q. Genetic Immunization [J]. Viral Immunology.1996; 9:1-9
[91]Ito H, Matumoto M. Protective efficacy of intranasal vaccination with subunit Sendai virus vaccine in mice [J]. Jpn J Exp Med.1986; 56(3):125-9
[92]Tashiro M, Homma M. Protection of mice from wild-type Sendai virus infection by a trypsin-resistant mutant, TR-2 [J]. J Virol.1985;53(1):228-34
[93]Fukumi H, Takeuchi Y. Vaccination against parainfluenza 1 virus (typus muris) infection in order to eradicate this virus in colonies of laboratory animals [J]. Dev Biol Stand.1975; 28:477-81
[94]Maru M, Haraguchi M, Sato K, Hotta H, Homma M. Evaluation of a protease activation mutant of Sendai virus as a potent live vaccine [J]. Vet Microbiol.1992; 30(1):1-12
[95]Tashiro M, Fujii Y, Nakamura K, Homma M. Cell-mediated immunity induced in mice after vaccination with a protease activation mutant, TR-2, of Sendai virus [J]. J Virol.1988; 62(7):2490-7
[96]Ito H, Matumoto M. Protective efficacy of intranasal vaccination with subunit Sendai virus vaccine in mice [J]. Jpn J Exp Med.1986; 56(3):125-9
[97]Kunisawa J, Nakagawa S, Mayumi T. Pharmacotherapy by intracellular delivery of drugs using fusogenic liposomes:application to vaccine development [J]. Adv Drug Deliv Rev.2001; 52(3):177-86
[98]Sato Y, Roman M, Tighe H, et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization [J]. Science.1996; 273(5):352-354
[99]Xiang ZQ, He Z, Wang Y, et al. The effect of interferon-gamma on genetic immunization [J]. Vaccine.1997; 15:896-902
[100]Iwasaki A, Stiemholm BJN, Chan AK, et al. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecule and cytokine [J]. J Immunol.1997; 158: 4591-4601
[101]An LL, Whitton JL. A multivalent minigene vaccine, containing B-cell, cytotoxic T-lymphocyte, and Th epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen [J]. J Virol.1997; 71(3):2292-302
[102]Kim JJ, Bagarazzi ML, Trivedi N, et al. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule gene [J]. Nat. Biotechnol.1997; 15: 641-645
[103]Tuting T, Wilson CC, Martin DM, et al. Autologous human monocyte derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic t-cell responses in vitro:enhancement by cotransfection of genes encoding the Th1-basing cytokines IL-12 and IFN-alpha [J]. J Immunol.1998; 1139-1147
[104]Eo SK, Sujin lee, Sangjun Chun, et al. Modulation of immunity against Herpes Simplex Virus infection via mucosal genetic transfer of plasmid DNA encoding chemokines [J]. J Virology. 2001; 569-578
[105]Eo SK, Lee S, Kumaraguru U, et al. Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands [J]. Vaccine.2001; 19(32):4685-4693
[106]Sin JI, Kim JJ, Pachuk C, et al. DNA Vaccines Encoding Interleukin-8 and RANTES enhance antigen-specific Thl-type CD4+T-cell-mediated Protective immunity against herpes simplex virus type 2 in vivo [J]. J Virol.2000; 74(23):1173-80
[107]Sin JI, Kim JJ, Zhang D, et al. Modulation of cellular responses by plasmid CD40L:CD40L plasmid vactor enhance antigen-specific helper T cell typel CD4+T cell-mediated protective immunity against herpes simplex virus type 2 in vivo [J]. Hum Gene Ther. 2001; 12(9):1091-102
[108]杜德伟,吴学勤,李谨革等.HBsAg DNA疫苗诱导小鼠特异性细胞和体液免疫[J].天 津医药.2001；29(4)：217-219
[109]Sixt N, Cardoso A, Vallier A, Fayolle J, Buckland R, Wild TF. Canine distemper virus DNA vaccination induces humoral and cellular immunity and protects against a lethal intracerebral challenge [J]. J Virol.1998; 72(11):8472-6
[110]Fujii Y, Sakaguchi T, Kiyotani K, Huang C, Fukuhara N, Egi Y, Yoshida T. Involvement of the leader sequence in Sendai virus pathogenesis revealed by recovery of a pathogenic field isolate from cDNA [J]. J Virol.2002;76(17):8540-7
[111]Hirata T, Iida A, Shiraki-Iida T, Kitazato K, Kato A, Nagai Y, Hasegawa M. An improved method for recovery of F-defective Sendai virus expressing foreign genes from cloned cDNA [J]. J Virol Methods.2002; 104(2):125-33
[112]Lagging LM, Meyer K, Hoft D, et al. Immune responses to plasmid DNA encoding the hepatitis C virus core protein [J]. J Virol.1995; 69:5859-5863
[113]Notkins A. L. Immune mechanisms by which the spread of viral infections is stopped [J]. Cell. Immunol.1974; 11:478-483
[114]Kano M, Matano T, Kato A, Shioda T, Nagai Y. Induction of HIV-1-specific neutralizing antibodies in mice vaccinated with a recombinant Sendai virus vector [J]. Jpn J Infect Dis.2002; 55(2):59-60
[115]Bocchia M, Bronte V, Colombo M, et al. Antitummor vaccination where we stand [J]. Haematologica.2000; 85:1172-206.
[116]Newman JT, Surman SR, Riggs JM, et al. Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse genetics [J]. Virus Genes.2002; 24(1):77-92
[117]Barouch DH, Santra S, Steenbake TD, et al. Augmentation and suppression of immune responses to an HIV-1DNA vaccine by plasmid cytokine/Ig administration [J]. J Immunol.1998; 161:1875-1882
[118]Lim YS, Kang BY, Kim EJ, et al. Potentition of antigen-specific, TH1 immune responses by multiple DNA vaccination with an ovalbumin/interferon-r hybridconstruct [J].Immunol.1998; 94:135-141
[119]Flo J, Tisminetzks, Baralle F, et al. Modulation of the immune response to DNA vaccine by co-deliveery of costimulatory molecules [J]. Immunology.2000; 100(2):259-67
[120]Yankanchas MA. Long-term anti-nucleoprotein cellular and containing NP gene [J]. Cell Biol.1993;4:151-59
[121]Griesenbach U, Inoue M, Hasegawa M, Alton EW. Sendai virus for gene therapy and vaccination [J]. Curr Opin Mol Ther.2005; 7(4):346-52.
[122]Maeda Y, Hatta M, Takada A, Watanabe T, Goto H, Neumann G, Kawaoka Y Live bivalent vaccine for parainfluenza and influenza virus infections [J]. J Virol,2005; 79(11):6674-9
[123]Kato M, Igarashi H, Takeda A, Sasaki Y, Nakamura H, Kano M, Sata T, Iida A, Hasegawa M, Horie S, Higashihara E, Nagai Y, Matano T. Induction of Gag-specific T-cell responses by therapeutic immunization with a Gag-expressing Sendai virus vector in macaques chronically infected with simian-human immunodeficiency virus [J]. Vaccine.2005; 23(24):3166-73.
[124]Takimoto T, Hurwitz JL, Zhan X, Krishnamurthy S, Prouser C, Brown B, Coleclough C, Boyd K, Scroggs RA, Portner A, Slobod KS. Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus [J]. Viral Immunol.2005; 18(2):255-66.
[125]Slobod KS, Shenep JL, Lujan-Zilbermann J, Allison K, Brown B, Scroggs RA, Portner A, Coleclough C, Hurwitz JL. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults [J]. Vaccine.2004; 22(23-24):3182-6.
[126]Takimoto T, Hurwitz JL, Coleclough C, Prouser C, Krishnamurthy S, Zhan X, Boyd K, Scroggs RA, Brown B, Nagai Y, Portner A, Slobod KS. Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV [J]. J Virol.2004; 78(11):6043-7.
[127]Nagase T, Matsumoto D, Nagase M, et al Neurospheres From Human Adipose Tissue Transplanted Into Cultured Mouse Embryos can Contribute to Craniofacial Morphogenesis:A Preliminary Report[J]. J Craniofac Surg.2007;18(1):49-53.
[128]Luque LE, Russell CJ.Spring-Loaded Heptad Repeat Residues Regulate the Expression and Activation of the Paramyxovirus Fusion (F) Protein[J]. J Virol.2007;24
[129]Marq JB, Brini A, Kolakofsky D, Garcin D. Targeting of the Sendai virus C protein to the plasma membrane via a peptide-only membrane anchor[J]. J Virol.2007; 17
[130]Kato A, Kiyotani K, Kubota T, et al. Importance of Anti-Interferon Capacity of the Sendai Virus C Protein for Pathogenicity in Mice[J]. J Virol.2007;10
[131]Kurooka M, Kaneda Y. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells[J]. Cancer Res.2007 Jan 1;67(1):227-36.
[132]Mottet-Osman G, Iseni F, Pelet T et al. Suppression of the Sendai virus M protein through a novel siRNA approach inhibits viral particle production but does not affect viral RNA synthesis[J]. J Virol.2006;27
[133]Pietila TE, Veckman V, Lehtonen A et al. Multiple NF-kappaB and IFN regulatory factor family transcription factors regulate CCL19 gene expression in human monocyte-derived dendritic cells[J]. J Immunol.2007;178(1):253-61.
[134]Park JH, Seok SH, Baek MW et al. Microbiological monitoring of Guinea pigs reared conventionally at two breeding facilities in Korea[J]. Exp Anim.2006;55(5):427-32
[135]Kiyotani K, Sakaguchi T, Kato A et al. Paramyxovirus Sendai virus V protein counteracts innate virus clearance through IRF-3 activation, but not via interferon, in mice[J]. Virology. 2006;5
[136]Kuo E, Bharat A, Shih J et al. Role of airway epithelial injury in murine orthotopic tracheal allograft rejection[J]. Ann Thorac Surg.2006;82(4):1226-33
[137]Yount JS, Kraus TA, Horvath CM et al. A novel role for viral-defective interfering particles in enhancing dendritic cell maturation[J]. J Immunol.2006;177(7):4503-13
[138]Quang Lea T, Kawachia M, Yamada H, et al. Identification of trypsin I as a candidate for influenza A virus and Sendai virus envelope glycoprotein processing protease in rat brain[J]. Biol Chem.2006;387(9):1305
[139]Shibata S, Okano S, Yonemitsu Y, et al. Induction of efficient antitumor immunity using dendritic cells activated by recombinant Sendai virus and its modulation by exogenous IFN-beta gene[J]. J Immunol.2006;177(6):3564-76
[140]Bousse T, Takimoto T. Mutation at residue 523 creates a second receptor binding site on human parainfluenza virus type 1 hemagglutinin-neuraminidase protein[J]. J Virol. 2006;80(18):9009-16
[141]Yoshizaki M, Hironaka T, Iwasaki H, et al. Naked Sendai virus vector lacking all of the envelope-related genes:reduced cytopathogenicity and immunogenicity[J]. J Gene Med. 2006;8(9):1151-9
[142]Yamada H, Le QT, Kousaka A, et al. Sendai virus infection up-regulates trypsin I and matrix metalloproteinase-9 Triggering viral multiplication and matrix degradation in rat lungs and lung L2 cells[J]. Arch Virol.2006; 151 (12):2529-37
[143]Bousse T, Chambers RL, Scroggs RA,et al. Human parainfluenza virus type 1 but not Sendai virus replicates in human respiratory cells despite IFN treatment[J]. Virus Res. 2006;121(1):23-32
[144]Hirayama E, Hattori M, Kim J. Specific binding of heat shock protein 70 with HN-protein inhibits the HN-protein assembly in Sendai virus-infected Vero cells[J]. Virus Res.2006 Sep;120(1-2):199-207
[145]Nishio M, Nagata A, Yamamoto A, et al. The properties of recombinant Sendai virus having the P gene of Sendai virus pi strain derived from BHK cells persistently infected with Sendai virus[J]. Med Microbiol Immunol.2006; 195(3):151-8
[146]石建党.普通棉耳狨猴死亡病毒病因及与人群关系的研究[D].天津：天津医科大学,2002：
[147]石立莹.副粘病毒Tianjin株全基因组克隆、测序及生物信息学分析[D].天津：天津医科大学,2007：
[148]张国际,李晓眠,佟惠春.仙台病毒HN基因核酸疫苗的构建及初步鉴定[J].天津医药2005；(33)1：17-19
[1]Homa FL, Brideau RJ, Lehman DJ, Thomsen DR, Olmsted RA, Wathen MW, Development of a novel subunit vaccine that protects cotton rats against both human respiratory syncytial virus and human parainfluenza virus type 3 [J]. J Gen Virol.1993; 74 (Pt 9):1995-9
[2]Counihan ME, Sha DK, Holman RC, et al. Human parainfluenza virus-associated hospitalizations among children less than five years of age in the United States [J]. Pediatr Infect Dis J.2001; 20(7):646-653
[3]Echevarria JE, Erdman DD, Meissner HC, et al. Rapid molecular epidemiologic studies of human parainfluenza viruse based on direct sequencing of amplified DNA from a multiplex RT-PCR assay [J]. J Virol Methods.2000; 88(1):105-109
[4]农光民,谢湘芝等.小儿呼吸道感染病毒病原学研究[J].广西医科大学学报.1996；13(4)：30-32
[5]金玉,李宇宁,段红梅等.兰州地区急性呼吸道感染患儿病毒病原学研究[J].中国当代儿科杂志.2001；3(3)：315-316
[6]王同权,何亚香,季正华.快速检测小儿肺炎病毒体1615例报告[J].苏州医学院学报.1995；15(1)：153
[7]陈文彬.副流感病毒疫苗研制近展[J].国外医学预防诊断治疗用生物制品分册.2004(27)2：57
[8]赵锴.病毒疫苗的研究现状与展望[J].第二军医大学学报2002；23(8)：813-815
[9]徐建青,司静懿,刘世德等.DNA疫苗[J].国外医学·免疫学分册.1998；21(2)：82-86
[10]张以芳,王生奎.影响核酸疫苗免疫效果的因素及提高核酸疫苗免疫效果的方法[J].黑龙江畜牧兽医.2000；3：24
[11]许崇波核酸疫苗研究进展[J].畜牧与兽医.1998；4：179-180
[12]赵平核酸疫苗作为治疗性疫苗的前景.免疫学杂志.2000；2：155-157
[13]薛强,仇华吉,童光志.RNA病毒的反向遗传学[J].生物技术通报2001；4：1
[14]Andrew Pekosz, Biao He, Robert A Lamb. Reverse genetics of negative-strand RNA viruses: Closing the circle [J]. Proc Natl Acad Sci USA,1999,96(16):8804-8806.
[15]Kawashita Y, Fujioka H, Ohtsuru A, Kaneda Y, Kamohara Y, Kawazoe Y, Yamashita S, Kanematsu T.The efficacy and safety of gene transfer into the porcine liver in vivo by HVJ (Sendai virus) liposome [J]. Transplantation.2005,15;80(11):1623-9.
[16]Nishiyama K, Takaji K, Kataoka K, Kurihara Y, Yoshimura M, Kato A, Ogawa H, Kurihara H. Idl gene transfer confers angiogenic property on fully differentiated endothelial cells and contributes to therapeutic angiogenesis [J]. Circulation.2005,112(18):2840-50.
[17]Itani T, Kobayashi Y, Kuroda M, Ma N, Mifuji R, Urawa N, Tanaka Y, Kaito M, Adachi Y. Transfecting the multidrug resistance protein 2 gene improves transcellular organic anion transport [J]. Int J Mol Med.2005,16(5):821-5.
[18]Griesenbach U, Inoue M, Hasegawa M, Alton EW. Sendai virus for gene therapy and vaccination [J]. Curr Opin Mol Ther.2005,7(4):346-52.
[19]Verma SK, Mani P, Sharma NR, Krishnan A, Kumar VV, Reddy BS, Chaudhuri A, Roy RP, Sarkar DP. Histidylated lipid-modified Sendai viral envelopes mediate enhanced membrane fusion and potentiate targeted gene delivery [J]. J Biol Chem.2005,280(42):35399-409.
[20]Zimmer G, Bossow S, Kolesnikova L, Hinz M, Neubert WJ, Herrler G.A chimeric respiratory syncytial virus fusion protein functionally replaces the F and HN glycoproteins in recombinant Sendai virus [J]. J Virol.2005,79(16):10467-77.
[21]Takimoto T, Hurwitz JL, Zhan X, Krishnamurthy S, Prouser C, Brown B, Coleclough C, Boyd K, Scroggs RA, Portner A, Slobod KS. Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus [J]. Viral Immunol.2005;18(2):255-66.
[22]Maeda Y, Hatta M, Takada A, Watanabe T, Goto H, Neumann G, Kawaoka Y Live bivalent vaccine for parainfluenza and influenza virus infections [J]. J Virol.2005,79(11):6674-9.
[23]Kato N, Nemoto K, Nakanishi K, Morishita R, Kaneda Y, Uenoyama M, Ikeda T, Fujikawa K. Nonviral HVJ (hemagglutinating virus of Japan) liposome-mediated retrograde gene transfer of human hepatocyte growth factor into rat nervous system promotes functional and histological recovery of the crushed nerve [J]. Neurosci Res.2005,52(4):299-310.
[24]Hou X, Suquilanda E, Zeledon A, Kacsinta A, Moore A, Seto J, McQueen N. Mutations in Sendai virus variant F1-R that correlate with plaque formation in the absence of trypsin [J]. Med Microbiol Immunol (Berl).2005,194(3):129-36.
[25]Shigemura N, Sawa Y, Mizuno S, Ono M, Ohta M, Nakamura T, Kaneda Y, Matsuda H. Amelioration of pulmonary emphysema by in vivo gene transfection with hepatocyte growth factor in rats [J]. Circulation.2005,22;111(11):1407-14.
[26]Li K, Chen Z, Kato N, Gale M Jr, Lemon SM. Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes [J]. J Biol Chem.2005, 29;280(17):16739-47.
[27]Ning S, Huye LE, Pagano JS. Regulation of the transcriptional activity of the IRF7 promoter by a pathway independent of interferon signaling [J]. J Biol Chem.2005,280(13):12262-70.
[28]Takimoto T, Hurwitz JL, Coleclough C, Prouser C, Krishnamurthy S, Zhan X, Boyd K, Scroggs RA, Brown B, Nagai Y, Portner A, Slobod KS. Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV [J]. J Virol.2004,78(11):6043-7.
[29]Wu MH, Yokozeki H, Takagawa S, Yamamoto T, Satoh T, Kaneda Y, Katayama I, Nishioka K. Hepatocyte growth factor both prevents and ameliorates the symptoms of dermal sclerosis in a mouse model of scleroderma [J]. Gene Ther.2004,11(2):170-80.
[30]NamikiM, Kawashima S, Yamashita T, Ozaki M, Sakoda T, Inoue N, Hirata K, Morishita R, Kaneda Y, Yokoyama M. Intramuscular gene transfer of interleukin-10 cDNA reduces atherosclerosis in apolipoprotein E-knockout mice [J]. Atherosclerosis.2004,172(1):21-9.
[31]Cai X, Castleman WL. Early high expression of IP-10 in F344 rats resistant to Sendai virus-induced airway injury [J]. Am J Physiol Lung Cell Mol Physiol.2003,285(6):L1263-9.
[32]Haller AA, Miller T, Mitiku M, Coelingh K. Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector [J]. J Virol.2000; 74(24):11626-35
[33]Tao T, Skiadopoulos MH, Davoodi F, Surman SR, Collins PL, Murphy BR. Construction of a live-attenuated bivalent vaccine virus against human parainfluenza virus (PIV) types 1 and 2 using a recombinant PIV3 backbone [J]. Vaccine.2001; 19(27):3620-31
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |